Recent Updates
Recently added Catalysts
INSM

Insmed To Present at the Cowen 42nd Annual Health Care Conference Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

Key Takeaway: BRIDGEWATER, N.J. , March 3, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the Cowen 42 nd Annual Health
Price reaction · baseline $23.77 (2022-03-02 close) · hit after-hours · 1 other INSM headline(s) in the window, move may be shared
day 0 close · peak
-2.8%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+47%
120-day peak, hindsight
Typical move
3.7%
average across 4 past catalysts
Cash runway
~39 mo
Minimal dilution risk
Lead asset
Brensocatib
Phase 3 · Non-Cystic Fibrosis Bronchiectasis

Full Press Release Details

BRIDGEWATER, N.J. , March 3, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the Cowen 42 nd Annual Health Care Conference on March 9, 2022 at 9:10 a.m. ET .
The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com . The webcast will be archived for a period of 30 days following the conclusion of the live event.
About Insmed Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States , Europe , and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey , with a growing footprint across Europe and in Japan . For more information, visit www.insmed.com .
Last updated: Mar 3, 2022